Latest statistics and disclosures from Sofinnova Management VIII's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Spark Therapeutics, Aclaris Therapeutics, Obseva Sa, Natera, Nucana Plc american depositary shares, and represent 88.65% of Sofinnova Management VIII's stock portfolio.
- Added to shares of these 2 stocks: Nucana Plc american depositary shares (+$12.25M), Synlogic, Inc. (+$8.08M).
- Started 2 new stock positions in Synlogic, Inc., Nucana Plc american depositary shares.
- Reduced shares in these 4 stocks: Versartis (-$27.28M), Spark Therapeutics (-$18.89M), Mirna Therapeutics, Innocoll Hldgs Plc shs.
- Sold out of its positions in Mirna Therapeutics, Versartis, Innocoll Hldgs Plc shs.
- Sofinnova Management VIII was a net seller of stock by $35.60M.
- Sofinnova Management VIII has $164.00M in assets under management (AUM), dropping by -8.09%.
Companies in the Sofinnova Management VIII portfolio as of September 2017 quarter
|Company (Ticker)||Portfolio Weight||Share Count||Change in Shares||Price|
|Nucana Plc american depositary shares||7.47||666666||NEW||18.37|
|Auris Med Hldg Ag||3.91||7.82M||0.82|
|Histogenics Corp Cmn||2.51||2.08M||1.98|